229 related articles for article (PubMed ID: 8729584)
1. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():11-5. PubMed ID: 8729584
[TBL] [Abstract][Full Text] [Related]
2. Development and pharmacology of fluvastatin.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):11-5. PubMed ID: 19489169
[TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetics of fluvastatin and specific drug interactions.
Smith HT; Jokubaitis LA; Troendle AJ; Hwang DS; Robinson WT
Am J Hypertens; 1993 Nov; 6(11 Pt 2):375S-382S. PubMed ID: 8297546
[TBL] [Abstract][Full Text] [Related]
4. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
5. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
[TBL] [Abstract][Full Text] [Related]
6. Clinical implications of the biopharmaceutical properties of fluvastatin.
Deslypere JP
Am J Cardiol; 1994 May; 73(14):12D-17D. PubMed ID: 8198018
[TBL] [Abstract][Full Text] [Related]
7. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
Harley CR; Gandhi S; Blasetto J; Heien H; Sasane R; Nelson SP
Am J Geriatr Pharmacother; 2007 Sep; 5(3):185-94. PubMed ID: 17996658
[TBL] [Abstract][Full Text] [Related]
8. The effect of fluvastatin on the pharmacokinetics and pharmacodynamics of ezetimibe.
Reyderman L; Kosoglou T; Cutler DL; Maxwell S; Statkevich P
Curr Med Res Opin; 2005 Aug; 21(8):1171-9. PubMed ID: 16083526
[TBL] [Abstract][Full Text] [Related]
9. Pharmacodynamics and pharmacokinetics of the HMG-CoA reductase inhibitors. Similarities and differences.
Lennernäs H; Fager G
Clin Pharmacokinet; 1997 May; 32(5):403-25. PubMed ID: 9160173
[TBL] [Abstract][Full Text] [Related]
10. Fluvastatin administration at bedtime versus with the evening meal: a multicenter comparison of bioavailability, safety, and efficacy.
Dujovne CA; Davidson MH
Am J Med; 1994 Jun; 96(6A):37S-40S. PubMed ID: 8017465
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of once-daily vs twice-daily dosing with fluvastatin, a synthetic reductase inhibitor, in primary hypercholesterolemia.
Insull W; Black D; Dujovne C; Hosking JD; Hunninghake D; Keilson L; Knopp R; McKenney J; Stein E; Troendle AJ
Arch Intern Med; 1994 Nov; 154(21):2449-55. PubMed ID: 7979841
[TBL] [Abstract][Full Text] [Related]
12. Use of an indirect effect model to describe the LDL cholesterol-lowering effect by statins in hypercholesterolaemic patients.
Faltaos DW; Urien S; Carreau V; Chauvenet M; Hulot JS; Giral P; Bruckert E; Lechat P
Fundam Clin Pharmacol; 2006 Jun; 20(3):321-30. PubMed ID: 16671968
[TBL] [Abstract][Full Text] [Related]
13. Fluvastatin for lowering cholesterol.
Med Lett Drugs Ther; 1994 May; 36(923):45-6. PubMed ID: 8177137
[No Abstract] [Full Text] [Related]
14. Influence of CYP2C9 polymorphisms on the pharmacokinetics and cholesterol-lowering activity of (-)-3S,5R-fluvastatin and (+)-3R,5S-fluvastatin in healthy volunteers.
Kirchheiner J; Kudlicz D; Meisel C; Bauer S; Meineke I; Roots I; Brockmöller J
Clin Pharmacol Ther; 2003 Aug; 74(2):186-94. PubMed ID: 12891229
[TBL] [Abstract][Full Text] [Related]
15. Lipid lowering therapy with fluvastatin and pravastatin in patients with HIV infection and antiretroviral therapy: comparison of efficacy and interaction with indinavir.
Benesic A; Zilly M; Kluge F; Weissbrich B; Winzer R; Klinker H; Langmann P
Infection; 2004 Aug; 32(4):229-33. PubMed ID: 15293079
[TBL] [Abstract][Full Text] [Related]
16. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
17. Impact of fluvastatin on hyperlipidemia after renal transplantation.
Tokumoto T; Tanabe K; Ishida H; Shimmura H; Ishikawa N; Goya N; Akiba T; Toma H
Transplant Proc; 2004 Sep; 36(7):2141-4. PubMed ID: 15518777
[TBL] [Abstract][Full Text] [Related]
18. Clinical pharmacokinetics of fluvastatin.
Scripture CD; Pieper JA
Clin Pharmacokinet; 2001; 40(4):263-81. PubMed ID: 11368292
[TBL] [Abstract][Full Text] [Related]
19. Clinical pharmacokinetics of statins.
García MJ; Reinoso RF; Sánchez Navarro A; Prous JR
Methods Find Exp Clin Pharmacol; 2003; 25(6):457-81. PubMed ID: 12949632
[TBL] [Abstract][Full Text] [Related]
20. A review of clinical trials comparing HMG-CoA reductase inhibitors.
Illingworth DR; Tobert JA
Clin Ther; 1994; 16(3):366-85; discussion 365. PubMed ID: 7923304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
